TORONTO, Aug. 27, 2018 (GLOBE NEWSWIRE) -- On Tuesday, Aug. 28, the Fraser Institute will release a new study on Canadian health-care policy.
Regulatory, Reimbursement and Pricing Barriers to Accessing Drugs for Rare Disorders in Canada spotlights how Canadians suffering from rare diseases, such as cystic fibrosis, could be affected by the Trudeau government’s proposed changes to the Patented Medicine Prices Review Board (PMPRB)—a federal body that regulates the prices of all patented medicines in Canada.
A news release with additional information will be issued via GlobeNewswire on Aug. 28 at 5:00 a.m. (Eastern).
MEDIA CONTACTS:
Dr. Nigel Rawson, Senior Fellow
Fraser Institute
To arrange media interviews or for more information, please contact:
Bryn Weese
Media Relations Specialist, Fraser Institute
(604) 688-0221 ext. 589
bryn.weese@fraserinstitute.org
Follow the Fraser Institute on Twitter | Like us on Facebook
The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, and Montreal and ties to a global network of think-tanks in 87 countries. Its mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. To protect the Institute’s independence, it does not accept grants from governments or contracts for research. Visit www.fraserinstitute.org